/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Cerus Corp

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.99 0.0642(6.42%) CERS at 04 Dec 2025 04:28 PM Medical Devices
Lowest Today 1.865
Highest Today 2.015
Today’s Open 1.87
Prev. Close 1.87
52 Week High 2.24
52 Week Low 1.12
Day’s Range: Low 1.865 High 2.015
52-Week Range: Low 1.12 High 2.24
1 day return -
1 Week return +13.06
1 month return +36.76
3 month return +49.06
6 month return +38.19
1 year return +11.79
3 year return -50.25
5 year return -72.32
10 year return -

Institutional Holdings

BlackRock Inc 10.81

ARK Investment Management LLC 10.02

Baker Bros Advisors LP 6.72

Vanguard Group Inc 5.59

ARK Disruptive Innovation Full Composite 5.54

ARK Innovation ETF 5.46

Wasatch Advisors LP 4.45

Wasatch Ultra Growth 4.02

ARK Genomic Revolution 3.54

ARK Genomic Revolution ETF 3.51

Sumitomo Mitsui Trust Group Inc 3.17

Amova Asset Management Americas, Inc 3.16

Vanguard Total Stock Mkt Idx Inv 2.83

Amova ARK Disruptive Innovation A USD 2.69

iShares Russell 2000 ETF 2.30

Geode Capital Management, LLC 2.27

RIMA MANAGEMENT, LLC 2.09

State Street Corp 2.00

D. E. Shaw & Co LP 1.96

Silvercrest Asset Management Group LLC 1.82

Millennium Management LLC 1.54

SILVERARC CAPITAL MANAGEMENT, LLC 1.30

IEQ CAPITAL, LLC 1.26

AQR Capital Management LLC 1.15

Goldman Sachs Group Inc 1.10

Vanguard Institutional Extnd Mkt Idx Tr 1.10

Morgan Stanley - Brokerage Accounts 1.07

Fidelity Small Cap Index 0.96

ING Investment Management LLC 0.88

BlackRock Advantage Small Cap Core Instl 0.87

iShares Russell 2000 Growth ETF 0.84

Northern Trust Corp 0.82

PRIMECAP Odyssey Aggressive Growth 0.69

Silvercrest U.S. Small Cap Growth 0.55

Fidelity Extended Market Index 0.55

BlackRock Advantage Small Cap Gr Instl 0.49

Schwab US Small-Cap ETF™ 0.49

Vanguard Russell 2000 ETF 0.46

State St Russell Sm Cap® Indx SL Cl I 0.34

Voya MI Dynamic Small Cap 0.32

Market Status

Strong Buy: 4

Buy: 0

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 359.20 M

PB Ratio 5.6411

PE Ratio 0.0

Enterprise Value 366.39 M

Total Assets 200.92 M

Volume 1958609

Company Financials

Annual Revenue FY24:180270000 180.3M, FY23:153633000 153.6M, FY22:162048000 162.0M, FY21:130859000 130.9M, FY20:91920000 91.9M

Annual Profit FY24:99522000 99.5M, FY23:84977000 85.0M, FY22:87094000 87.1M, FY21:67384000 67.4M, FY20:50763000 50.8M

Annual Net worth FY24:-20918000 -20.9M, FY23:-49785000 -49.8M, FY22:-42825000 -42.8M, FY21:-54376000 -54.4M, FY20:-59857000 -59.9M

Quarterly Revenue Q3/2025:52698000 52.7M, Q2/2025:52445000 52.4M, Q1/2025:43239000 43.2M, Q4/2024:50809000 50.8M, Q3/2024:46017000 46.0M

Quarterly Profit Q3/2025:28140000 28.1M, Q2/2025:28975000 29.0M, Q1/2025:25424000 25.4M, Q4/2024:27385000 27.4M, Q3/2024:26199000 26.2M

Quarterly Net worth Q3/2025:-19000 -0.0M, Q2/2025:-5707000 -5.7M, Q1/2025:-7717000 -7.7M, Q4/2024:-2521000 -2.5M, Q3/2024:-2934000 -2.9M

Fund house & investment objective

Company Information Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

Organisation Medical Devices

Employees 614

Industry Medical Devices

CEO Mr. William M. Greenman

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow